Resources

[1] Alain Micaleff, Kimberley Hockley, Diana Hughes, Lawrence Philips, Nan Wang, Davide Luciani, TorbjornCallreus, Deborah Ashby, On behalf of the IMI-PROTECT Work Package 5 participants. Benefit Risk Wave 1 Case study Report Efalizumab, Feb 2013.